Formulation: A solid
Formal Name: 2,5-dihydro-2,5-dioxo-1H-pyrrole-1-hexanoic acid, 2-[1-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-hydroxyethylidene]hydrazide, hydrochloride
Purity: ≥95%
Formula Markup: C37H42N4O13 • HCl
Formula Weight: 787,2
Shelf life (days): 1460
CAS Number: 480998-12-7
Notes: Aldoxorubicin is a prodrug form of the anthracycline antitumor antibiotic doxorubicin (Item No. 15007).{61877} Aldoxorubicin selectively binds to serum albumin, which releases doxorubicin in acidic environments, such as the tumor microenvironment. It inhibits the proliferation of RenCa renal cell carcinoma cells as well as MCF-7 breast and LXFL 529 lung cancer cells (IC50s = 1, 1.1, and 0.5 µM, respectively). Aldoxorubicin (39.3 µmol/kg) induces tumor regression in an MDA-MB-435 breast cancer mouse xenograft model. Unlike doxorubicin, aldoxorubicin is not toxic to mice (LD50 = >60 mg/kg).{61878} It has also been used to conjugate doxorubicin to antibodies.{61879}
English
Deutsch
